EULAR 2018 Review

More documents

Recommendations

Info

References • Aramaki T, Kojima K, Kurushima S, Tsuji Y, Kawachi N, Iwamoto N, Ichinose K, Terada K, Eguchi K, Ueki Y, Kawakami A. Efficacy and safety of tofacitinib (TOF) in patients with rheumatoid arthritis at 52 weeks in clinical practice. Abstract 0500. • Behrens F, Gomez-Reino J, Nash P, Gladman DD, FitzGerald O, Ritchlin C, Kudlacz E, Wu J, Wang C, Romero AB. Impact of baseline demographics, disease activity and concomitant medication on American College of Rheumatology 20 response rate and Health Assessment Questionnaire-Disability Index score with tofacitinib in active psoriatic arthritis: a pooled subgroup analysis of 2 Phase 3 studies. Abstract 0921. • Bingham III CO, Gaich C, DeLozier AM, Quebe A, Sun L, Otawa S, Pope J. Converting patient-reported outcome measures of fatigue and pain to PROMIS scores: data from Phase 3 baricitinib rheumatoid arthritis trials. Abstract 0106. • Bingham III CO, Gaich C, DeLozier AM, Quebe A, Sun L, Otawa S, Pope J. Converting patient-reported physical function outcomes scores to PROMIS metric scores in Phase 3 trials of baricitinib in rheumatoid arthritis. Abstract 0013. • Burmester G, Kremer JM, van den Bosch F, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS. A Phase 3 randomized, placebo-controlled, double-blind study of upadacitinib (ABT-494), a selective JAK-1 inhibitor, in patients with active rheumatoid arthritis with inadequate response to conventional synthetic DMARDS. Abstract 0036. • Burmester G, Rigby WFC, Choy E, Nash P, Winthrop K, Mease PJ, Young P, Hendrikx T, Wang C, Menon S, Graham D. Changes in lymphocytes and lymphocyte subsets in tofacitinib-treated patients with psoriatic arthritis. Abstract 0330. • Bykerk VP, van Vollenhoven R, Connell C, Gruben D, Fallon L, Woolcott J, Keystone E. Identification of distinct disease activity trajectories in patients with rheumatoid arthritis receiving tofacitinib over 12 months. Abstract 0217. • Calabrese LH, Abud-Mendoza C, Lindsey S, Lee S-H, Takiya L, Iikuni N, Soma K, Luo Z, Fleischmann R. Evaluation of live zoster vaccine in a subset of patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, and adalimumab with methotrexate: results from a Phase 3b/4 randomised trial. Abstract 0220. • Chastek B, Koep E, Mallya UG, Cockerham A, Choi J, Boklage S, Furst DE. Real-world interruptions in janus kinase inhibitor therapy observed among biologic-naïve and biologic-experienced rheumatoid arthritis patients. Abstract 0177. • de Vlam K, Fautrel B, van de Laar M, Kirkham BW, Alten R, Van Beneden K, de Leonardis F, Lopez-Romero P, Gaich C, Quebe A, Cardoso A, Fleischmann R, Emery P. Impact of controlling disease activity on regaining normal physical function, and achieving no or limited pain in patients with rheumatoid arthritis treated with baricitinib. Abstract 0258. • Diller M, Hülser M-L, Hasseli R, Rehart S, Müller-Ladner U, Neumann E. JAK-inhibition with peficitinib and filgotinib in fibroblast-like synoviocytes in rheumatoid arthritis. Abstract 0492. • FitzGerald O, Rubbert-Roth A, Chen K, Meerwein S, Enejosa J, Shaw T, Wells AF. Rapid response with upadacitinib treatment in patients with rheumatoid arthritis and an inadequate response to csDMARDS or bDMARDS. Abstract 0239. • Fleischmann R, Wollenhaupt J, Cohen S, Smolen JS, Dahl P, Iikuni N, Shi H, Tatulych S, Takiya L. Impact of glucocorticoids on efficacy and safety of tofacitinib with and without methotrexate and adalimumab with methotrexate for rheumatoid arthritis: results from a Phase 3B/4 randomised trial. Abstract 0247. • Gaylis N, Sagliani J, Needell S. Adjusting the dose of tofacitinib to achieve optimal results in the management of patients with active rheumatoid arthritis (RA) may offer more successful results than utilizing a standard fixed one dose approach. Abstract 0282. • Genovese MC, Fleischmann R, Combe B, Hall S, Zhang Y, Zhou Y, Mohamed MF, Meerwein S, Pangan AL. Upadacitinib in patients with active rheumatoid arthritis and inadequate response or intolerance to biological dmards: a Phase 3 randomized, placebo-controlled, double-blind study of a selective JAK1 inhibitor. Abstract 0219. • Genovese MC, Kremer J, Zhong S, Friedman A. Long-term safety and efficacy of upadacitinib (ABT-494), an oral JAK-1 inhibitor in patients with rheumatoid arthritis in an open label extension study. Abstract 0236. • Harigai M, Winthrop K, Takeuchi T, Hsieh T-Y, Chen Y-M, Smolen JS, Burmester GR, Walls C, Wu W-S, Dickson C, Liao R, Genovese MC. Hepatitis B virus reactivation in patients with rheumatoid arthritis treated with baricitinib: post-hoc analysis from clinical trials. Abstract 0077.
• Helliwell P, Coates LC, FitzGerald O, Nash P, Soriano ER, Husni ME, Hsu M-A, Kanik KS, Hendrikx T, Wu J, Kudlacz E. Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis. Abstract 0323. • Hsieh T-Y, Huang W-N, Tony H-P, Balsa A, Winthrop K, Harigai M, Dickson C, Wu W-S, de la Torre I, Liao R, Chen L, Kumar S, Combe B. Hepatic safety in patients with rheumatoid arthritis who received isoniazid for latent tuberculosis: post-hoc analysis from Phase 3 baricitinib studies. Abstract 0098. • Kaine J, Tesser J, DeMasi R, Takiya L, Wang L, Snyder M, Fan H, Bandi V, Wollenhaupt J. Efficacy of tofacitinib after temporary discontinuation in patients with rheumatoid arthritis: analysis of data from open-label long-term extension studies. Abstract 0037. • Karakoc Y, Ercan I. Drug survival analysis of tofacitinib in patients with rheumatoid arthritis. Abstract 0502. • Kivitz AJ, FitzGerald O, Nash P, Pang S, Azevedo VF, Kudlacz E, Wang C, Graham D, Takiya L. Efficacy of tofacitinib by background methotrexate dose in patients with psoriatic arthritis: a post-hoc analysis of pooled data from 2 Phase 3 trials. Abstract 0902. • Kragstrup TW, Mellemkjær A, Nielsen M, Heftdal L, Schafer P, Deleuran B. A MAPK activated kinase 2 inhibitor attenuates inflammatory and destructive arthritis in human ex vivo models. Abstract 0096. • Kume K, Amano K, Yamada S, Kanazawa T, Hatta K, Kuwaba N. Tofacitinib improves left ventricular mass and cardiac output in rheumatoid arthritis patients with chronic heart failure. Abstract 0489. • Li Z, Hu J, Bao C, Li X, Li X, Xu J, Spindler A, Zhang X, Xu J, Li Z, Wang G, Sun J, Ji F, Tao H, Zhan L, Rooney T, Zerbini C. Efficacy and safety of baricitinib in MTX-IR patients with rheumatoid arthritis: 52 week results from a Phase 3 study (RA-BALANCE). Abstract 0218. • Lopez-Olivo MA, Tayar JH, Zamora NV, Pratt G, Suarez-Almazor ME. Malignancies and serious infections in randomized controlled trials of janus kinase inhibitors in patients with rheumatoid arthritis: a systematic review and meta-analysis. Abstract 0032. • Luchikhina EL, Karateev D, Loukina G, Borisova M, Demidova N, Nasonov E. Comparative efficacy of tofacitinib and biologic dmards in patients with rheumatoid arthritis with insufficient response to subcutaneous methotrexate in clinical practice. Abstract 0485. • Martinez Gamboa LM, Bang H, Issa M, Zuckerman S, Cardoso A, Holzkaemper T, De Leonardis F, de la Torre I, Tanaka Y, Feist E. Autoantibody profiling for response to baricitinib in patients with rheumatoid arthritis and no or limited exposure to methotrexate. Abstract 0109. • Marzaioli V, Canavan M, Wade S, Low C, Veale DJ, Fearon U. Tofacitinib impairs monocyte-derived dendritic cell differentiation in rheumatoid arthritis and psoriatic arthritis. Abstract 0046. • Masterson T, Klein K, Karouzakis E, Distler O, Ospelt C, Bertoncelj MF. Joint-specific differences in the activation of the JAK-STAT pathway in rheumatoid arthritis. Abstract 0165. • Mease PJ, Kremer J, Cohen S, Curtis JR, Charles-Schoeman C, Loftus Jr EV, Greenberg J, Palmetto N, Kanik KS, Graham D, Wang C, Biswas P, Chan G, DeMasi R, Valdez H, Hendrikx T, Jones TV. Incidence of thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programmes. Abstract 0243. • Mohamed M-EF, Coppola S, Feng T, Anderson J, Othman AA. Characterization of the effect of renal impairment on upadacitinib pharmacokinetics. Abstract 0479. • Mohamed M-EF, Coppola S, Feng T, Lacerda AP, Othman AA. Mild and moderate hepatic impairment have no clinically relevant impact on upadacitinib pharmacokinetics: results from a dedicated Phase 1 study. Abstract 0478. • Mok CC, Wan R, Fong B. Prevalence and risk factors of serious infections in rheumatoid arthritis patients receiving the biologic/targeted synthetic DMARDS: a propensity score analysis from the Hong Kong biologics registry. Abstract 0425. • Mueller R, Popp F, Mattow F, Durmisi M, Souza A, Schulze-Koops H, Hasler P, von Kempis J. Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen and Aarau cohort. Abstract 0497. • Muraviev Y, Radenska-Lopovok S, Lebedeva V, Alamankina S. Nodular polyarteritis as an unforeseeable adverse reaction in RA patient treated with tofacitinib. Abstract 0413. • Nash P, Coates LC, Kivitz AJ, Mease PJ, Gladman DD, Covarrubias-Cobos JA, Fleishaker D, Wang C, Kudlacz E, Menon S, Fallon L, Hendrikx T, Kanik KS. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of OPAL Balance, an open-label, long-term extension study. Abstract 0293.
Page 1 and 2: Enhancing knowledge of the clinical
Page 3 and 4: Highlights from EULAR 2018 During t
Page 5 and 6: Poster Sessions Poster Tour: Novel
Page 7 and 8: Poster sessions I, II and III Upada
Page 9 and 10: treatment with tofacitinib lead to
Page 11 and 12: Baricitinib dose step-down followin
Page 13 and 14: Publication only Efficacy and safet
Page 15 and 16: A case study of vasculitis in a pat
Page 17: In a separate dedicated Phase 1 stu
Page 21: Enhancing knowledge of the clinical

EULAR 2018 Review

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?